De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Dermapharm Holding Toekomstige groei
Future criteriumcontroles 3/6
Dermapharm Holding zal naar verwachting groeien in winst en omzet met respectievelijk 20% en 3.8% per jaar. De winst per aandeel zal naar verwachting groeien met 20% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 18.5% zijn.
Belangrijke informatie
20.0%
Groei van de winst
20.0%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 19.7% |
| Inkomstengroei | 3.8% |
| Toekomstig rendement op eigen vermogen | 18.5% |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 29 Aug 2024 |
Recente toekomstige groei-updates
Recent updates
Here's Why Dermapharm Holding (ETR:DMP) Has A Meaningful Debt Burden
Sep 28
Dermapharm Holding SE Beat Revenue Forecasts By 6.7%: Here's What Analysts Are Forecasting Next
Aug 31Dermapharm Holding SE's (ETR:DMP) P/E Still Appears To Be Reasonable
Aug 17It Looks Like Dermapharm Holding SE's (ETR:DMP) CEO May Expect Their Salary To Be Put Under The Microscope
Jun 21These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Extensively
Apr 29Dermapharm Holding SE's (ETR:DMP) Price In Tune With Earnings
Feb 07Dermapharm Holding (ETR:DMP) Seems To Use Debt Quite Sensibly
Dec 15An Intrinsic Calculation For Dermapharm Holding SE (ETR:DMP) Suggests It's 24% Undervalued
Nov 17Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet
Aug 28Dermapharm Holding SE's (ETR:DMP) Intrinsic Value Is Potentially 76% Above Its Share Price
Aug 01Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet
May 29Is Dermapharm Holding SE (ETR:DMP) Trading At A 44% Discount?
May 03Dermapharm Holding's (ETR:DMP) Soft Earnings Are Actually Better Than They Appear
Apr 04We Think Dermapharm Holding (ETR:DMP) Can Stay On Top Of Its Debt
Feb 22Is Dermapharm Holding (ETR:DMP) A Risky Investment?
Nov 17Is Dermapharm Holding (ETR:DMP) A Risky Investment?
Aug 16Is Dermapharm Holding (ETR:DMP) A Risky Investment?
May 18Is Dermapharm Holding (ETR:DMP) Using Too Much Debt?
Feb 17These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Reasonably Well
Nov 19Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?
Aug 21Is Dermapharm Holding SE (ETR:DMP) Trading At A 28% Discount?
Jul 31Is Dermapharm Holding SE (ETR:DMP) The Right Choice For A Smart Dividend Investor?
May 03Calculating The Intrinsic Value Of Dermapharm Holding SE (ETR:DMP)
Apr 16Here's Why Dermapharm Holding (ETR:DMP) Can Manage Its Debt Responsibly
Mar 25Did You Miss Dermapharm Holding's (ETR:DMP) Impressive 110% Share Price Gain?
Mar 07Is Dermapharm Holding SE's (ETR:DMP) 27% ROE Better Than Average?
Feb 15Something To Consider Before Buying Dermapharm Holding SE (ETR:DMP) For The 1.4% Dividend
Jan 29Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?
Dec 24
The Dermapharm Holding (ETR:DMP) Share Price Has Gained 45% And Shareholders Are Hoping For More
Dec 07Dermapharm Holding SE Just Missed Earnings - But Analysts Have Updated Their Models
Nov 18Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2026 | 1,284 | 138 | 166 | 225 | 4 |
| 12/31/2025 | 1,220 | 127 | 152 | 210 | 5 |
| 12/31/2024 | 1,166 | 103 | 162 | 207 | 5 |
| 6/30/2024 | 1,147 | 83 | 146 | 187 | N/A |
| 3/31/2024 | 1,129 | 57 | 137 | 179 | N/A |
| 12/31/2023 | 1,151 | 62 | 178 | 219 | N/A |
| 9/30/2023 | 1,172 | 95 | 240 | 279 | N/A |
| 6/30/2023 | 1,151 | 123 | 267 | 304 | N/A |
| 3/31/2023 | 1,128 | 146 | 287 | 323 | N/A |
| 12/31/2022 | 1,041 | 134 | 250 | 289 | N/A |
| 9/30/2022 | 1,024 | 176 | 222 | 269 | N/A |
| 6/30/2022 | 1,004 | 185 | 191 | 249 | N/A |
| 3/31/2022 | 980 | 211 | 190 | 252 | N/A |
| 12/31/2021 | 960 | 210 | 189 | 250 | N/A |
| 9/30/2021 | 902 | 162 | 153 | 209 | N/A |
| 6/30/2021 | 858 | 123 | 115 | 164 | N/A |
| 3/31/2021 | 828 | 95 | 96 | 139 | N/A |
| 12/31/2020 | 808 | 86 | 90 | 131 | N/A |
| 9/30/2020 | 775 | 80 | 60 | 104 | N/A |
| 6/30/2020 | 760 | 77 | 58 | 97 | N/A |
| 3/31/2020 | 743 | 85 | 69 | 114 | N/A |
| 12/31/2019 | 714 | 77 | 54 | 101 | N/A |
| 9/30/2019 | 674 | 73 | 51 | 90 | N/A |
| 6/30/2019 | 639 | 77 | 70 | 109 | N/A |
| 3/31/2019 | 611 | 73 | 84 | 115 | N/A |
| 12/31/2018 | 584 | 75 | 133 | 159 | N/A |
| 9/30/2018 | 558 | 75 | 143 | 165 | N/A |
| 6/30/2018 | 525 | 76 | 62 | 137 | N/A |
| 3/31/2018 | 498 | 79 | N/A | 120 | N/A |
| 12/31/2017 | 480 | 78 | N/A | 87 | N/A |
| 9/30/2017 | 486 | 84 | N/A | 84 | N/A |
| 12/31/2016 | 455 | 77 | N/A | 77 | N/A |
| 12/31/2015 | 396 | 13 | N/A | 40 | N/A |
| 12/31/2014 | 402 | 0 | N/A | 54 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei DMP ( 20% per jaar) ligt boven de spaarquote ( 0.8% ).
Winst versus markt: De winst van DMP ( 20% per jaar) zal naar verwachting sneller groeien dan de German markt ( 20.2% per jaar).
Hoge groeiwinsten: De winst van DMP zal naar verwachting de komende 3 jaar aanzienlijk groeien.
Omzet versus markt: De omzet van DMP ( 3.8% per jaar) zal naar verwachting langzamer groeien dan de markt German ( 5.4% per jaar).
Hoge groei-inkomsten: De omzet van DMP ( 3.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen DMP zal naar verwachting over 3 jaar laag zijn ( 18.5 %).